Success Rates Can Improve Through ERA and PGS
The pace of modernization has pushed a number of couples to choose to become parents at a later stage of their lives. Studies show that there is an increase in 33% of women giving birth over the age of 40, in the last five years.
“Inability of conceiving naturally pushes couples towards assisted reproduction such as IVF. According to a study revealed by IGENOMIX, 25% of couples worldwide fail in trying to conceive naturally,” says Dr. Rajni Khajuria, Laboratory Manager, IGENOMIX.
Planning and opting for IVF pregnancy is itself a big task for any couple. There are cases when a woman faces a miscarriage or even repetitive IVF failures even after successful implantations. There are many factors that contribute to IVF failures. Over 50% of spontaneous miscarriages are caused by chromosomal abnormalities. Chromosomal abnormalities also cause birth defects and the risks of having a child with such abnormalities increases with advanced maternal and paternal age. IVF fails if the uterus lining is not healthy. For example, women suffering from Polycystic ovary syndrome (PCOS) may face more difficulty in conceiving.
IVF failures are disheartening. IGENOMIX’s ERA (Endometrial Receptivity Analysis) & PGS (Preimplantation Genetic Screening) helps couples who are undergoing multiple IVF failures by increasing their chances of successful pregnancy.
The ERA test assesses receptivity status of endometrium and determines whether or not the patient’s endometrium had a receptive gene profile at the time of biopsy. “25% of the embryo transfers are done in the wrong day. ERA Test by IGENOMIX informs about the correct window of implantation (WOI), hence increasing the pregnancy rate with personalized embryo transfer by 60%,” says Dr. Rajni Khajuria. Preimplantation Genetic Screening (PGS) for aneuploidy is a powerful genetic test that may be performed on embryos during IVF treatment to screen for numerical chromosomal abnormalities. PGS is performed on a small embryo biopsy prior to transfer and identifies which embryos are chromosomally normal. It also comes with the advantage of MitoScore that helps selects the embryo with maximum chances of implantation.
IGENOMIX is a biotechnology company providing advanced services in reproductive genetics. Its consolidated experience and advanced research capabilities make it one of the world leaders in this field and guarantee the provision of effective solutions tailored to different infertility problems. It is present in Valencia (Spain), Miami, Los Angeles, New York, Mexico City, Sao Paulo, Dubai and Delhi, with a workforce of over 170 professionals.
Further information about the company at https://www.igenomix.co.in/
Media contact: Divya Bhasin email@example.com +91-11-6651-7800 Marketing Manager – India & UAE IGENOMIX